Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response Rates in Genotype 1 CHC Patients with Insulin Resistance and Prolonged Treatment in Late Virological Responders
2006-000757-21Phase 3Terminated
- Sponsor
- AESCA Pharma
- Start
- Jul 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of peginterferon alfa-2b and ribavirin in chronic hepatitis C virus infection, sponsored by AESCA Pharma. Primary endpoint: Early virological response rate by insulin resistance status. Started Jul 2006; status: terminated.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on 2006-000757-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000757-21.